In a recent post on the IVI-sponsored Health Affairs featured blog series, Robert Galvin and Troyen Brennan make the case for employers and pharmacy benefit managers to challenge drug manufacturers’ pricing models as a means of keeping costs in check, particularly in regard to launch prices. They suggest a strategy in which employers and pharmacy benefit managers refuse to provide coverage for drugs that do not meet an objectively derived threshold for cost effectiveness.
Read the full article here.
About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.
